Haleon plc (NYSE:HLN) Holdings Cut by State Street Corp

State Street Corp reduced its stake in shares of Haleon plc (NYSE:HLN) by 1.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 380,279 shares of the company’s stock after selling 5,059 shares during the period. State Street Corp’s holdings in Haleon were worth $4,023,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC raised its position in Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after acquiring an additional 5,768,117 shares in the last quarter. Sculptor Capital LP raised its holdings in shares of Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after purchasing an additional 3,592,000 shares in the last quarter. Clearbridge Investments LLC lifted its stake in shares of Haleon by 8.6% in the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after purchasing an additional 3,307,009 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Haleon by 95.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock valued at $16,143,000 after purchasing an additional 954,622 shares during the last quarter. Finally, Natixis Advisors LLC boosted its holdings in Haleon by 142.5% in the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after purchasing an additional 866,070 shares in the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Stock Down 1.3 %

Shares of HLN opened at $9.51 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The company has a 50-day simple moving average of $9.68 and a 200-day simple moving average of $9.62. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80. The firm has a market capitalization of $43.05 billion, a P/E ratio of 27.97, a P/E/G ratio of 2.95 and a beta of 0.28.

Analyst Ratings Changes

A number of brokerages have weighed in on HLN. UBS Group raised Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley boosted their target price on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Haleon currently has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.